Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCI) will likely be releasing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Treace Medical Concepts to post earnings of ($0.15) per share and revenue of $61.7630 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

Treace Medical Concepts Stock Performance

Shares of NASDAQ TMCI opened at $2.01 on Tuesday. Treace Medical Concepts has a 12 month low of $1.81 and a 12 month high of $10.03. The stock has a 50 day moving average of $2.40 and a 200-day moving average of $4.52. The company has a current ratio of 3.37, a quick ratio of 2.36 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $128.08 million, a P/E ratio of -2.51 and a beta of 0.74.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TMCI. XTX Topco Ltd acquired a new stake in shares of Treace Medical Concepts in the 4th quarter valued at approximately $180,000. Quadrature Capital Ltd acquired a new stake in shares of Treace Medical Concepts during the 4th quarter valued at $149,000. Moore Capital Management LP grew its position in Treace Medical Concepts by 50.5% during the 4th quarter. Moore Capital Management LP now owns 222,110 shares of the company’s stock worth $544,000 after acquiring an additional 74,503 shares during the last quarter. Engineers Gate Manager LP acquired a new position in shares of Treace Medical Concepts in the fourth quarter valued at approximately $109,000. Finally, Jain Global LLC acquired a new position in shares of Treace Medical Concepts in the fourth quarter valued at approximately $184,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Wednesday, January 21st. BTIG Research reaffirmed a “neutral” rating on shares of Treace Medical Concepts in a research report on Friday, November 7th. UBS Group lowered their target price on Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $5.00 price objective (down from $8.00) on shares of Treace Medical Concepts in a report on Friday, November 7th. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $4.21.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.